Blueprint Medicines Q2 2020 Earnings Report
Key Takeaways
Blueprint Medicines reported second-quarter 2020 financial results, featuring $5.7 million in net product revenue from AYVAKIT sales and a collaboration with Roche for pralsetinib. The company is on track to report top-line data from EXPLORER and PATHFINDER trials and submit a supplemental NDA to the FDA.
Recorded $5.7 million in net revenue for AYVAKIT (avapritinib).
Initiated registration-enabling Part 2 of PIONEER trial of avapritinib in indolent SM.
Received positive CHMP opinion for avapritinib for PDGFRA D842V mutant GIST in EU.
Entered into global collaboration with Roche for pralsetinib, including $775 million in upfront payments.
Blueprint Medicines
Blueprint Medicines
Forward Guidance
Based on its current operating plans, Blueprint Medicines expects that its existing cash, cash equivalents and investments, together with the upfront payments under its collaboration with Roche and anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.